EPR: Investing in the future of pharmaceutical microbiology QC

In a recent article with European Pharmaceutical Review (EPR), Troy Wright, Senior Vice President and Global Head of Quality at Abzena, shared his thoughts on the major challenges facing pharmaceutical microbiology quality control.

There has been an increased demand for faster turnaround times for microbiological results. This has meant that rapid microbiology methods have been gaining more visibility in the pharmaceutical microbiology industry. This is especially true for cell and gene therapy programs. Here there is an urgency to deliver safe and quality product to patients within days.

“In most companies, QC microbiology is a small unit that does not get the attention needed to deliver safe and quality products to patients in a timely manner.”

Given the importance of quality control in pharmaceutical microbiology, Abzena are focused on the future of our updated QC labs and are investing in people, surrounding processes, and advanced technologies.

In this article you’ll discover how the sector’s importance can often be overlooked, despite its key role in bringing safe, quality products to market.

Read the full article here